Earnings Call Transcripts
Access detailed transcripts and key takeaways from company earnings calls
All Earnings Calls
Axe Compute FY2025 Earnings Call - $12M in Contracts, $43M Compute Reserve, $8.6M Market Cap Disconnect
Axe Compute used the FY2025 investor presentation to reposition itself as an emerging GPU infrastructure reseller, touting rapid commercial traction while confronting a messy accounting history tied t...
- Management repositioned the company as Axe Compute after a strategic expansion into AI infrastructure and a rebrand completed in December 2025, with the new CEO in place since February 2026 and a newly named president starting now.
- Company reported roughly $12 million in total contract value signed in the prior month, translating to an expected monthly contract value of approximately $850,000 entering Q2, or about $7.7 million of contracted income for 2026.
- More than 20 enterprise customers and over 30 active deployments were reported live, according to management statements on the call.
- +16 more takeaways
Conagra Brands Third Quarter Fiscal 2026 Earnings Call - Returned to Organic Growth as Frozen and Snacks Drive Momentum; FCF Lift Narrows Guidance
Conagra returned to organic net sales growth in Q3, posting 2.4% organic growth as frozen and snacks powered the recovery. Frozen volumes rebounded strongly, with roughly 88% of the frozen portfolio h...
- Conagra returned to organic net sales growth in Q3, up 2.4% year over year.
- Volume was modestly positive at +0.5%, with price and mix contributing +1.9% to organic growth.
- Frozen and snacks were the clear growth engines: refrigerated and frozen net sales rose 3.6% driven by nearly 4% volume growth, and snacks outpaced category growth for the fifth consecutive quarter.
- +15 more takeaways
Ascend Wellness Holdings Q4 2025 Earnings Call - Cost Cuts and CPG Strength Offset Industry Price Compression
Ascend walked a tightrope in 2025, using cost cuts, retail densification and heavy CPG innovation to blunt steep market-wide price compression. Revenue slid, mostly from a deliberate pullback in lower...
- Top line softened, with Q4 revenue of $120.5 million, down 3.4% sequentially and full-year revenue of $500.6 million, down 10.9% versus 2024.
- Management prioritized retail verticalization, routing biomass to finished goods, which drove retail to ~70.5% of Q4 revenue and reduced wholesale exposure.
- Wholesale revenue declined materially, down 13.1% quarter-over-quarter and 15% year-over-year, hit by price compression and intentional mix shifts away from low-margin bulk sales.
- +11 more takeaways
Algonquin Power & Utilities Corp. Q4 2025 Earnings Call - Balance sheet repair and regulatory wins underpin pivot to premium regulated utility, higher tax rate trims 2027 EPS
Algonquin spent 2025 rebuilding credibility with markets and regulators, and the results show it. The company used proceeds from the sale of its renewables business to pay down about $1.6 billion of d...
- Algonquin is repositioning as a pure-play regulated utility, emphasizing operational discipline, regulatory engagement, and a simplified portfolio.
- Full year 2025 GAAP net earnings were $208 million, up from $54.8 million in 2024; full year Adjusted Net Earnings were $258.8 million, up about 17% year over year.
- 2025 full year Adjusted Net EPS was $0.34, a 13% increase from $0.30 in 2024, and exceeded guidance by $0.02 per share.
- +14 more takeaways
Nephros, Inc. Fourth Quarter 2025 Earnings Call - 33% Revenue Growth and Second Straight Profitable Year, Tariffs Pinch Margins
Nephros reported a strong 2025, with total revenue up 33% to $18.8 million and the company posting net income of about $1.2 million, its second consecutive profitable year. Growth was driven by progra...
- Nephros delivered 33% full-year revenue growth in 2025, rising to $18.8 million from $14.2 million in 2024.
- Fourth quarter 2025 net revenue was $4.7 million, up 22% year over year.
- Net income for 2025 was approximately $1.2 million, compared with $0.1 million in 2024, marking the company’s second consecutive profitable year.
- +16 more takeaways
Cohen & Company Q4 2025 Earnings Call - SPAC-led investment bank fuels a 246% revenue surge, but founder-share mechanics and concentrated pipeline raise volatility questions
Cohen & Company closed 2025 with a blowout top line, reporting $275.6 million of revenue for the year, up 246% from 2024, driven almost entirely by its full-service boutique investment bank, Cohen & C...
- Full-year 2025 revenue was $275.6 million, up 246% versus 2024.
- Adjusted pre-tax income for full-year 2025 was $41.4 million, equal to 15% of total revenue.
- Cohen & Company Capital Markets (CCM) produced $184 million of revenue in 2025, up 370% year over year, and represented 67% of company revenue for the year.
- +12 more takeaways
Faraday Future Q4 2025 Earnings Call - Pivot to EAI ecosystem as robotics deliver revenue and positive product gross margins
Faraday Future says 2025 was a turning point, moving from strategy into execution by positioning itself as an embodied AI, or EAI, ecosystem. The company rolled a pre-production FX Super One off its C...
- Company framing: Faraday Future says 2025 marked a shift from strategy to execution, repositioning as an embodied AI ecosystem platform built on a dual-engine model, EAI EV plus EAI robotics.
- Robotics go-to-market: FF EAI Robotics launched on February 4, deliveries began in late February 2026, cumulative shipments including pre-deliveries reached 22 units by March 2026, and cumulative non-binding, non-refundable pre-orders surpassed 1,200 units.
- Robotics economics: Management reports that robotics already generated product sales revenue and achieved a positive product gross margin in the first quarter following launch, positioning robotics as a capital efficient cash generator.
- +11 more takeaways
Venu Holding Corporation Q4 2025 Earnings Call - $1.24B Appraised Portfolio and $86M Raise Power Rapid Venue Build-Out
Venu spent 2025 converting investor faith into steel, partners, and a clearer playbook. Management closed an $86 million raise, reported a third-party as-completed appraisal of $1.24 billion for its p...
- Venu completed an $86 million capital raise during a difficult market stretch, boosting cash and liquidity.
- Independent appraisal values Venu's portfolio at $1.24 billion on an as-completed basis, implying just over $12 per share fully diluted.
- Total assets on the balance sheet rose to $370 million as of December 31, 2025, up 108% year-over-year.
- +12 more takeaways
RH FY 2025 Earnings Call - Peak Investment Year; Estates Launch and Global Galleries Set the Stage for Strong Margin Leverage
RH reported a solid 2025 operating year despite running a self-declared peak investment cycle. Revenue grew 8% (15% over two years), adjusted EBITDA rose to $597 million (17.3% of sales) and free cash...
- 2025 was a peak investment year: revenue +8% (15% two-year), adjusted EBITDA $597M (17.3% of revenues) vs $539M (16.9%) in 2024, and free cash flow turned positive to $252M from -$214M year-over-year.
- RH invested heavily in 2025: $289M adjusted CapEx plus $37M to acquire Michael Taylor Designs, Formations, and Dennis & Leen to fuel RH Estates.
- RH Estates launches this spring with RH Bespoke Furniture and RH Couture Upholstery, targeting the traditional/classic luxury home market that RH says represents ~60% of luxury homes.
- +14 more takeaways
eXoZymes Q4 2025 Earnings Call - Kilo-scale, >99% pure NCT validates cell-free platform and launches commercial NCTx push
eXoZymes used 2025 to pivot from a broad synbio playbook to a product-first commercial push, and presented a concrete proof point: cell-free production of NCT at pilot/kilo scale with industry-grade p...
- Company pivoted in 2025 from broad partnerships to owning and advancing flagship assets to capture more upside for shareholders.
- eXoZymes and partner Cayman Chemical achieved pilot/kilo-scale production, yielding over 0.5 kg of ultra-pure NCT, a major proof of tech transferability and scaleability for the cell-free platform.
- NCT is presented as a potent HNF4α agonist, acting on mitochondrial energy utilization rather than appetite suppression; diet-induced obesity mouse data showed roughly 30%–40% less weight gain on identical calories with improved liver fat and mitochondrial markers.
- +12 more takeaways